Home / Market News / $NVO
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Bernstein Research Adjusts Novo Nordisk Price Target

Nov 6, 2026, 1:02 PM UTC · Primary ticker $NVO

Bernstein Research increased its price target for Novo Nordisk from DKK 203 to DKK 223, but crucially maintained an 'Underperform' rating. This indicates that while the firm sees some upside, they still believe the stock will underperform the broader market, with their long-term estimates significantly below consensus.

Bernstein Research adjusted its price target for Novo Nordisk upwards, from DKK 203 to DKK 223. However, the key takeaway is the firm's continued 'Underperform' rating, signaling a bearish outlook despite the higher target. This matters because it suggests that even with a more optimistic valuation, Bernstein believes Novo Nordisk's stock will underperform its peers, with their 2026-2031 projections remaining up to 17% below consensus. For traders, this presents a short-term opportunity to consider the implications of a major research firm maintaining a negative stance, potentially leading to downward pressure on the stock, despite the seemingly positive price target increase. The long-term implication is that the market may need to re-evaluate its consensus expectations if other analysts follow suit.

$NVO negative Underperform rating maintained despite price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.